Free tool
FAERS Monitor: Zidovudine
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 200732 or its brand name (Zidovudine, Zidovudine). Reports on generic versions are filed under their own applications.
Reports
10,367
Serious
9,840
95% of reports
Hospitalization
2,189
Death reported
1,459
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- foetal exposure during pregnancy1,625
- virologic failure778
- drug resistance709
- anaemia617
- exposure during pregnancy588
- pathogen resistance585
- drug exposure during pregnancy580
- viral mutation identified567
- premature baby497
- maternal exposure during pregnancy428
- treatment failure420
- lipodystrophy acquired413
- death385
- pyrexia372
- drug ineffective341
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 342 |
| 2005 | 319 |
| 2006 | 479 |
| 2007 | 447 |
| 2008 | 445 |
| 2009 | 480 |
| 2010 | 459 |
| 2011 | 347 |
| 2012 | 282 |
| 2013 | 298 |
| 2014 | 344 |
| 2015 | 534 |
| 2016 | 1,064 |
| 2017 | 902 |
| 2018 | 740 |
| 2019 | 607 |
| 2020 | 706 |
| 2021 | 405 |
| 2022 | 359 |
| 2023 | 357 |
| 2024 | 174 |
| 2025 | 136 |
| 2026 | 139 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,792 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| lipodystrophy acquiredSignal | 413 | 489.7 | 440.6 | 161,892 |
| viral mutation identifiedSignal | 567 | 368.9 | 338.0 | 175,757 |
| virologic failureSignal | 778 | 342.9 | 318.6 | 226,684 |
| pathogen resistanceSignal | 585 | 139.1 | 128.2 | 74,949 |
| drug resistanceSignal | 709 | 57.6 | 53.6 | 38,308 |
| foetal exposure during pregnancySignal | 1,625 | 41.4 | 39.5 | 62,933 |
| drug exposure during pregnancySignal | 580 | 35.2 | 32.5 | 18,933 |
| premature babySignal | 497 | 34.0 | 31.2 | 15,670 |
| exposure during pregnancySignal | 588 | 19.4 | 17.9 | 10,158 |
| treatment failureSignal | 420 | 10.3 | 9.4 | 3,527 |
| maternal exposure during pregnancySignal | 428 | 9.8 | 8.9 | 3,365 |
| anaemiaSignal | 617 | 6.6 | 6.1 | 2,932 |
| pyrexiaSignal | 372 | 2.2 | 2.0 | 241 |
| death | 385 | 0.9 | 0.8 | 4 |
| drug ineffective | 341 | 0.5 | 0.5 | 156 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.